Refractive Error and Biometry in Retinopathy of Prematurity

Refractive and Biometric Outcomes in Patients With Retinopathy of Prematurity Treated With Intravitreal Injection of Ranibizumab as Compared With Bevacizumab - a Clinical Study of Correction at Three Years of Age

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03334513

Enrollment

Registered

2017-11-07

Start date

2011-04-01

Completion date

2014-04-01

Last updated

2017-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of Prematurity

Keywords

Bevacizumab, Biometry, Ranibizumab, Refractive error, Retinopathy of prematurity

Brief summary

The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.

Detailed description

Purpose: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of Ranibizumab (IVR), versus bevacizumab (IVB), at a corrected age of 3 years. Methods: A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for Type 1 ROP, from April 2011 to April 2014. Comparison of refractive errors and biometric findings between the two groups was performmed and multivariate analysis of possible factors contributive to visual acuity was also performmed

Interventions

DRUGBevacizumab

intravitreal injection of bevacizumab

DRUGRanibizumab

intravitreal injection of ranibizumab

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

3 Years to 3 Years

Healthy volunteers

Inclusion criteria

* children with type 1 retinopathy of prematurity * children received anti-vascular endothelial growth factors (bevacizumab or ranibizumab)

Exclusion criteria

* children withour retinopathy of prematurity * children with retinopathy of prematurity received laser therapy

Design outcomes

Primary

Measure	Time frame	Description
spherical equivalent	at corrected age of 3 year-old	spherical power + half of cylinder power
astigmatism	at corrected age of 3 year-old	in cylinder power

Secondary

Measure	Time frame	Description
axial length	at corrected age of 3 year-old	axial length in mm
cornea radius	at corrected age of 3 year-old	cornea radius in mm
anterior chamber depth	at corrected age of 3 year-old	anterior chamber depth in mm
lens thickness	at corrected age of 3 year-old	lens thickness in mm

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026